ArticleEuropean journal of epidemiology2026
VITALITY - a longitudinal cohort established to assess the role of postnatal vitamin D supplementation in atopic disease and immune health.
Article in European journal of epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
VITALITY was established as a single-centre, doubleblind, randomised controlled trial (RCT) to determine whether daily supplementation of 400 International Units (IU) of vitamin D in the first year of life reduces the prevalence of food allergy at 12 months of age, compared to placebo. It recruited 2739 healthy, term, breastfed infants from 2014 to 2022 in Greater Melbourne, Australia. With an overall high retention rate despite the COVID-19 pandemic of over 83%, VITALITY is a rich cohort with extensive samples and data at baseline (six-12 weeks) and at six-, nine- and 12-months of age. Questionnaires collected information on demographics and environmental exposure, allergic diseases, infant feeding and factors thought to influence vitamin D levels at all timepoints. The majority of participants had a family history of allergic disease (89.2%) and 61.2% had both parents born in Australia. The standardized clinic visit at 12 months of age, attended by 79% of participants, included skin prick tests (SPT) +/- oral food challenges (OFC) and eczema assessment. Biospecimen collection included blood, skin and nasal swabs, stool and breastmilk which can be used for multi-omics profiling. Overall we performed SPTs on 2151 infants and undertook 612 OFCs. A six year follow up of VITALITY participants is underway and will determine the effect of early-life vitamin D supplementation on outcomes of asthma and other allergic diseases, lung function, infection and oral health. VITALITY is a large longitudinal cohort with data collected at multiple timepoints in childhood on a range of health outcomes. It provides a unique opportunity to explore early-life risk factors including genetic and environmental markers for food allergy, asthma, other atopic and non-communicable diseases as the cohort matures, in addition to establishing the role of vitamin D as an early-life strategy for prevention of disease and sustaining immune health.
Indexed as
Identifiers
42862263What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.